SBSilvia Bagnoli

Silvia Bagnoli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Silvia Bagnoli has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multimodal Detection of Cognitive Impairment in Non-Neurological Rehabilitation Settings: The COGinREHAB Study Protocol

    by Sara Della Bella, Giulia Martinelli, Eleonora Pavan, Pietro Davide Trimarchi, Angela Comanducci, Assunta Ingannato, Silvia Bagnoli, Benedetta Nacmias, Franca Rosa Guerini, Marina Saresella, et al.

    Background/Objectives: Cognitive impairment is highly prevalent among hospitalised adults but often remains under-recognised, particularly in non-neurological rehabilitation settings where clinical attention is mainly focused on physical recovery. Undetected cognitive impairment may adversely affect rehabilitation outcomes, functional recovery, and long-term care planning. Methods: A multicentre, prospective, longitudinal study, with a single-group assignment and a diagnostic purpose, will be conducted across three rehabilitation centres of the Don Carlo Gnocchi Foundation (Italy), enrolling 384 patients aged ≥45 years without severe psychiatric or neurological disorders, other than cognitive impairment, admitted to cardiac, pulmonary, orthopaedic rehabilitation, or intermediate care units for non-neurological conditions. At baseline (T0), all participants will undergo standardised clinical and cognitive screening. Individuals with suspected cognitive impairment, operationally defined as an Equivalent Score (ES) of 1 on the Montreal Cognitive Assessment–MoCA total score and/or an ES of 0 or 1 on at least one MoCA cognitive domain, including the Memory Index Score (MIS), and a random sample of those without, will undergo a comprehensive neuropsychological assessment. Participants with neuropsychologically defined cognitive impairment, based on objective deficits in the comprehensive neuropsychological assessment, will undergo plasma biomarker testing (GFAP, NfL, pTau-217), APOE genotyping, and brain CT. Participants with a MoCA total ES of 0 will be classified as having cognitive impairment on the basis of screening alone. At two prespecified sites, consecutive consenting participants with neuropsychologically defined cognitive impairment will additionally undergo an EEG vigilance protocol, auditory P300 recording, seven-day actigraphy, and overnight polysomnography. Patients with neuropsychologically defined cognitive impairment at T0 will undergo a 12-month follow-up assessment (T1) of the progression of cognitive impairment and plasma biomarkers; those enrolled in the neurophysiological substudy will additionally repeat the EEG vigilance protocol. Expected Results: The study will provide a conservative (lower-bound) estimate of the prevalence of documented and non-documented cognitive impairment, together with an estimate corrected for partial verification bias, in non-neurological rehabilitation settings. It will further characterise the cognitive profiles and examine their correlations with biomarkers of neurodegeneration (GFAP, NfL, pTau-217), APOE genotype, relative EEG spectral power and sleep intrusion measures, P300 latency and amplitude, actigraphy-derived Sleep Efficiency, and polysomnography-derived sleep stage proportions. Longitudinal data will enable the evaluation of cognitive trajectories and their biological correlates. Conclusions: The COGinREHAB study addresses a critical gap in rehabilitation medicine by implementing a structured, multimodal approach to the identification and characterisation of cognitive impairment in patients with non-neurological conditions. Its findings may facilitate earlier detection of cognitive impairment and inform the development of personalised rehabilitation and care pathways. Trial registration: ClinicalTrials.gov, NCT07731334.

  • Open Access

    Cumulative Incidence in Monogenic Alzheimer’s Disease and Frontotemporal Dementia: Gene–Gene Interaction Effect

    by Andrea Geviti, Lorenzo Pagano, Mario Grassi, Claudia Saraceno, Alessandro Facconi, Silvia Fostinelli, Valentina Laganà, Giulia Giacomucci, Maria Sofia Cotelli, Valentina Cantoni, et al.

    Monogenic forms of Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD) represent the two principal neurodegenerative disorders leading to early-onset dementia, primarily linked to mutations in key AD- and FTD-associated genes. The marked heterogeneity in age at onset and penetrance among carriers of pathogenic mutations suggests that monogenic variants act within a broader polygenic background. The combined impact of AD- and FTD-related genetic variation on disease incidence in monogenic forms remains largely unexplored. Herein, we investigate gene–gene interaction patterns in monogenic AD and FTD, with a focus on genetic variability in key AD (APP, PSEN1, PSEN2) and FTD (MAPT, GRN, C9orf72)-associated genes and their association with cumulative disease incidence. Within the GARDENIA Consortium, we studied 426 individuals from Italian pedigrees, including patients (n = 319) and presymptomatic (n = 107) carriers of causative variants in APP (n = 39), PSEN1 (n = 71), PSEN2 (n = 13), MAPT (n = 29), GRN (n = 188), and C9orf72 (n = 86). Age at symptoms onset, age at last follow-up and sex were recorded. Whole exome sequencing was performed, focusing on non-causative variants (n = 64) in the key AD (APP, PSEN1, PSEN2) and FTD genes (MAPT, GRN, C9orf72). Weighted genetic burden scores were derived using Fine–Gray competing risk models to estimate variant-specific effects on cumulative AD and FTD incidence, accounting for mutually exclusive outcomes and family clustering. Model fit was evaluated using Akaike Information Criterion. Higher AD-risk-weighted burden scores in AD-related genes were associated with a significantly increased cumulative incidence of AD, while higher FTD-risk-weighted scores in FTD-related genes showed a trend toward association with increased cumulative incidence of FTD. A significant interaction between burden scores was observed. AD and FTD burden scores showed a negative interaction for AD (~79% attenuation) but a modest synergistic effect for FTD (~6% increase). These findings could imply context-dependent pleiotropy rather than simple additive genetic effects. Our study suggests that even in carriers oh highly penetrant AD or FTD causative variants, genetic background could substantially modulate cumulative disease incidence. Integrating polygenic information with monogenic status may improve prognostic stratification and inform precision approaches in dementia research and clinical trials.

  • Miglustat does not impact clinical progression in patients with spastic paraplegia type 11

    by Serena Mero, Ivana Ricca, Salvatore Rossi, Sabato Mellone, Olimpia Musumeci, Gianmarco Dalla Zanna, Elena Michelucci, Silvia Bagnoli, Benedetta Nacmias, Alessandra Tessa, et al.

    Spastic paraplegia type 11 (SPG11) is a progressive neurological condition with no treatment. Possible involvement of abnormal ganglioside metabolism has been reported in mouse and human cells. Preclinical data in zebrafish and fruit fly models of the disease indicate that miglustat can improve biochemical parameters and locomotion. We assessed the short-term safety of oral miglustat in patients with SPG11. This was an open-label, single center, non-randomized, phase II study. All patients received miglustat orally (4 weeks 100 mg/tid and 8 weeks 200 mg/tid). The primary outcome was the frequency of adverse events (AEs), particularly and severe AEs (SAEs), emerging in the course of the study. As secondary outcomes we measured clinical severity scores, functional tests, and biomarkers at 3 and 6 months. Twelve-week treatment with miglustat was adequately tolerated, with only minor AEs and no SAEs reported. With a few exceptions, the treatment did not seem to impact neuromotor function in patients with SPG11. Although it showed an acceptable safety profile and no SAEs, miglustat did not significantly modify plasma sphingolipid and ganglioside profiles. Its potential therapeutic impact remains low.


  • “Assessing relationship between blood MAPT methylation levels and clinical expression in Frontotemporal Dementia”

    by Gemma Lombardi, Silvia Bagnoli, Assunta Ingannato, Alice Finocchi, Silvia Campagnini, Silvia Fostinelli, Antonio Longobardi, Roberta Ghidoni, Giuliano Binetti, Barbara Borroni, et al.

    Introduction Little is known regarding the relationship between methylation levels and Frontotemporal Dementia (FTD). Objective The objective of the present study was to assess the relationship between blood MAPT methylation levels and clinical expression in FTD. Methods This cross-sectional observational study was conducted including 54 Italian patients with different phenotypes: 22 behavioral variant FTD (bvFTD), 10 semantic variant (svPPA), 22 non-fluent variant (nfv) Primary Progressive Aphasia (PPA). Results Results reveal a negative correlation between MAPT methylation levels determined by pyrosequencing analysis and the severity of disease in the FTD group and highlight an association between nfvPPA variant and intermediate-high levels of MAPT methylation, which persists also considering disease severity. Conclusions Our findings allow us to speculate that the degree of MAPT methylation in the blood, a test minimally invasive, cost-effective, and easily repeatable could be useful to differentiate FTD variants at onset and to confirm disease stage in symptomatic FTD patients. Further studies, also with a longitudinal design, are warranted to confirm our results.


  • Open Access

    Evaluation of Illumina and Oxford Nanopore Sequencing for the Study of DNA Methylation in Alzheimer’s Disease and Frontotemporal Dementia

    by Lorenzo Pagano, Davide Lagrotteria, Alessandro Facconi, Claudia Saraceno, Antonio Longobardi, Sonia Bellini, Assunta Ingannato, Silvia Bagnoli, Tommaso Ducci, Alessandra Mingrino, et al.

    DNA methylation is a critical epigenetic mechanism involved in numerous physiological processes. Alterations in DNA methylation patterns are associated with various brain disorders, including dementias such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Investigating these alterations is essential for understanding the pathogenesis and progression of these disorders. Among the various methods for detecting DNA methylation, DNA sequencing is one of the most widely employed. Specifically, two main sequencing approaches are commonly used for DNA methylation analysis: bisulfite sequencing and single-molecule long-read sequencing. In this review, we compared the performances of CpG methylation detection obtained using two popular sequencing platforms, Illumina for bisulfite sequencing and Oxford Nanopore (ON) for long-read sequencing. Our comparison considers several factors, including accuracy, efficiency, genomic regions, costs, wet-lab protocols, and bioinformatics pipelines. We provide insights into the strengths and limitations of both methods with a particular focus on their application in research on AD and FTD.


  • Open Access

    Mutational Landscape of Alzheimer’s Disease and Frontotemporal Dementia: Regional Variances in Northern, Central, and Southern Italy

    by Claudia Saraceno, Lorenzo Pagano, Valentina Laganà, Andrea Geviti, Silvia Bagnoli, Assunta Ingannato, Salvatore Mazzeo, Antonio Longobardi, Silvia Fostinelli, Sonia Bellini, et al.

    Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD) are the two major neurodegenerative diseases with distinct clinical and neuropathological profiles. The aim of this report is to conduct a population-based investigation in well-characterized APP, PSEN1, PSEN2, MAPT, GRN, and C9orf72 mutation carriers/pedigrees from the north, the center, and the south of Italy. We retrospectively analyzed the data of 467 Italian individuals. We identified 21 different GRN mutations, 20 PSEN1, 11 MAPT, 9 PSEN2, and 4 APP. Moreover, we observed geographical variability in mutation frequencies by looking at each cohort of participants, and we observed a significant difference in age at onset among the genetic groups. Our study provides evidence that age at onset is influenced by the genetic group. Further work in identifying both genetic and environmental factors that modify the phenotypes in all groups is needed. Our study reveals Italian regional differences among the most relevant AD/FTD causative genes and emphasizes how the collaborative studies in rare diseases can provide new insights to expand knowledge on genetic/epigenetic modulators of age at onset.


  • Open Access

    Disentangling empathy impairment along Alzheimer's disease continuum: From subjective cognitive decline to Alzheimer's dementia

    by Giulia Giacomucci, Valentina Moschini, Diletta Piazzesi, Sonia Padiglioni, Cecilia Caruso, Claudia Nuti, Alice Munarin, Salvatore Mazzeo, Giulia Galdo, Cristina Polito, et al.


  • Open Access

    The Huntington’s Disease Gene in an Italian Cohort of Patients with Bipolar Disorder

    by Camilla Ferrari, Elena Capacci, Silvia Bagnoli, Assunta Ingannato, Sandro Sorbi, Benedetta Nacmias

    Background and objectives: Huntington’s disease (HD) is characterized by motor, cognitive and psychiatric manifestations and caused by an expansion of CAG repeats over 35 triplets on the huntingtin (HTT) gene. However, expansions in the range 27–35 repeats (intermediate allele) can be associated with pathological phenotypes. The onset of HD is conventionally defined by the onset of motor symptoms, but psychiatric disturbances can precede the motor phase by up to twenty years. The aims of the present study are to identify HD patients in the pre-motor phase of the disease among patients diagnosed with bipolar disorders and evaluate any differences between bipolar patients carrying the normal HTT allele and patients with the expanded HTT gene. Methods: We assessed the HTT genotype in an Italian cohort of 69 patients who were affected by either type 1 or type 2 bipolar disorder. Results: No patient was found to be a carrier of the pathological HTT allele, but 10% of bipolar subjects carried an intermediate allele. Carriers of the intermediate allele were older at the onset of psychiatric symptoms than non-carriers. Conclusion: The pathological HTT gene was not associated with bipolar disorder, while we found a higher frequency of the intermediate allele among the bipolar population with respect to healthy controls. The identification of this subset of bipolar subjects has implications for the clinical management of patients and their family members and promotes further investigation into possible pathological mechanisms common to both HD and bipolar disorder.

  • Open Access

    The Huntington’s Disease Gene in an Italian Cohort of Patients With Bipolar Disorder

    by Camilla Ferrari, Elena Capacci, Silvia Bagnoli, Assunta Ingannato, Sandro Sorbi, Benedetta Nacmias

    Background and objectives: Huntington disease (HD) is characterized by motor, cognitive and psychiatric manifestations and is caused by an expansion of CAG repeats over 35 triplets on the huntingtin (HTT) gene. However, expansions in the range 27-35 repeats (intermediate allele) can be associated with pathological phenotypes. The onset of HD is conventionally defined by the onset of motor symptoms, but psychiatric disturbances can precede the motor phase by up to twenty years. The aims of the present study are to identify HD patients in the pre-motor phase of the disease among patients diagnosed with bipolar disorders and to evaluate any differences between bipolar patients carrying normal HTT allele and patients with expanded HTT gene. Methods: We assessed the HTT genotype in an Italian cohort of 69 patients affected by bipolar disorder type 1 and type 2. Results: No patient was found to be a carrier of the pathological HTT allele, but 10% of bipolar subjects carried an intermediate allele. Carriers of the intermediate allele were older at onset of psychiatric symptoms than non-carriers. Conclusion: The pathological HTT gene was not associated with bipolar disorder, while we found a higher frequency of the intermediate allele among the bipolar population with respect to healthy controls.

  • Open Access

    Plasma neurofilament light chain predicts Alzheimer’s disease in patients with subjective cognitive decline and mild cognitive impairment: a longitudinal study

    by Salvatore Mazzeo, Silvia Bagnoli, Assunta Ingannato, Sonia Padiglioni, Giulia Giacomucci, Alberto Manganelli, Valentina Moschini, Juri Balestrini, Arianna Cavaliere, Carmen Morinelli, et al.

    Background: We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer’s disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Methods: This longitudinal cohort study involved 140 patients (50 with SCD, 73 with MCI, and 22 with AD dementia [AD-D]) who underwent plasma NfL and AD biomarker assessments (CSF, amyloid-PET, and 18 F-FDG-PET) at baseline. They were rated according to the A/T/N system and followed up for a mean time of 2.72±0.95 years to detect progression from SCD to MCI and from MCI to AD. Forty-eight patients (19 SCD, 29 MCI) also underwent plasma NfL measurements after two years after baseline. Results: At baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N-) with high accuracy (AUC=0.82). We identified cut-off value of 19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow-up, nine SCD patients progressed to MCI (p-SCD), and 14 MCI patients developed AD dementia (p-MCI). The previously identified cut-off values provided good accuracy in identifying p-SCD (80% [95% C.I.=65.69:94.31]). The rate of NfL change was higher in p-MCI (3.52±4.06 pg/mL) compared to np-SCD (0.81±1.25 pg/mL) and np-MCI (−0.13±3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC=0.954). Conclusion: Plasma NfL concentration and change over time may be a reliable, non-invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease. Key messages: What is already known on this topic Plasma NfL increase in SCD, MCI and AD and longitudinal changes in NfL are related to changes in brain atrophy and cognitive outcomes in AD. Nevertheless, the clinical value of plasma NfL in non-demented patients has been poorly explored. What this study adds Plasma NfL accurately predicts AD pathology and progression of cognitive decline in SCD and MCI. Repeated measurements of NfL may further increase the accuracy of this biomarker How this study might affect research, practice, or policy Given its accessibility, blood-based NfL can assist clinicians in determining the optimal personalized diagnostic and therapeutic approach for individuals presenting with SCD or MCI, providing insights into the underlying biological mechanisms of cognitive decline, even in primary care settings.